Structure-Based Drug Design to Identify Potent, Selective, and Orally Available Cyclin-Dependent Kinase 9 Inhibitors for the Treatment of Castration-Resistant Prostate Cancer

Key Points

• This research aims to identify effective inhibitors targeting CDK9 for prostate cancer treatment.
• Utilized structure-based drug design techniques to develop inhibitors.
• Focused on compounds that are potent, selective, and orally available.
• Targeted cyclin-dependent kinase 9 to combat castration-resistant prostate cancer.
• Identified new inhibitors with potential therapeutic effects for castration-resistant prostate cancer.
• Demonstrated the capability of these inhibitors to overcome androgen receptor dependency.